Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apomorphine subcutaneous - NeuroHealing Pharmaceuticals

Drug Profile

Apomorphine subcutaneous - NeuroHealing Pharmaceuticals

Alternative Names: NH-001

Latest Information Update: 06 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroHealing Pharmaceuticals
  • Developer Cato Research; NeuroHealing Pharmaceuticals
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Coma
  • New Molecular Entity No
  • Available For Licensing Yes - Coma

Highest Development Phases

  • Suspended Coma

Most Recent Events

  • 26 Apr 2013 NeuroHealing Pharmaceuticals suspends enrolment in its Phase-II trial for Coma in USA (NCT00761228)
  • 23 May 2011 NeuroHealing Pharmaceuticals receives Orphan Drug status for apomorphine for Coma in European Union
  • 16 May 2011 NeuroHealing Pharmaceuticals and Cato BioVentures (Cato Research) agree to co-develop apomorphine for Coma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top